Luca I.
- Country
- Italy
- Department
- Dipartimento di Medicina, Unità di Reumatologia
Research Overview
- Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Evaluation of Ianalumab Efficacy, Safety, and Tolerability in Diffuse Cutaneous Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study
Data & Insights
Has run more than one trial at 82 of 127 partner sites.
Specializations
Autoimmune Disorders
The investigator specializes in the study of diffuse cutaneous systemic sclerosis (dcSSc), a complex autoimmune condition affecting skin and internal organs.
- Systemic Sclerosis Management
- Autoimmune Disease Therapeutics
- Skin Fibrosis Treatment
Their research explores innovative therapeutic approaches for managing systemic sclerosis manifestations.
Clinical Assessment
The investigator focuses on evaluating treatment outcomes using the Revised Composite Response Index in Systemic Sclerosis (CRISS) methodology.
- Disease Activity Measurement
- Treatment Response Assessment
- Clinical Outcome Evaluation
Their work involves comprehensive assessment of therapeutic interventions in systemic sclerosis.
Therapeutic Development
The investigator is involved in advancing novel treatments for autoimmune conditions, with particular emphasis on targeted therapeutic approaches.
- Innovative Treatment Strategies
- Biological Therapy Assessment
- Treatment Safety Evaluation
Their research encompasses the evaluation of new therapeutic options for systemic sclerosis patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.